


PHARMACEUTICAL 2022



VACCINEX INC. Rank 425 of 466







PHARMACEUTICAL 2022



VACCINEX INC.Rank 425 of 466

The relative strengths and weaknesses of VACCINEX INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of VACCINEX INC. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 19% points. The greatest weakness of VACCINEX INC. is the variable Net Income, reducing the Economic Capital Ratio by 239% points.

The company's Economic Capital Ratio, given in the ranking table, is -157%, being 235% points below the market average of 78%.

| Input Variable | Value in 1000 USD |
|---|----------------------|
| Assets, Current | 9,405 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 0 |
| Liabilities, Current | 2,256 |
| Liabilities, Non-Current | 175 |
| Other Assets | 141 |
| Other Compr. Net Income | 0 |
| Other Expenses | 809 |
| Other Liabilities | 0 |
| Other Net Income | 919 |
| Other Revenues | 900 |
| Property and Equipment | 297 |
| Research and Development | 17,160 |
| Selling, General and Administrative Expense | 6,230 |

| Output Variable | Value in 1000 USD |
|--------------------------|----------------------|
| Assets | 9,843 |
| Liabilities | 2,431 |
| Expenses | 24,199 |
| Revenues | 900 |
| Stockholders Equity | 7,412 |
| Net Income | -22,380 |
| Comprehensive Net Income | -22,380 |
| Economic Capital Ratio | -157% |

